Accessibility Menu
Kura Oncology logo

Kura Oncology

(NASDAQ) KURA

Current Price$10.89
Market Cap$966.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-27%
5 Year-41%
1 Year+71%
1 Month+16%
Kura Oncology last closing stock price
MetricPriceDate
Last closeUSD 10.892026-07-16
Kura Oncology stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-9.85%USD 12.082026-07-09
1 month+15.85%USD 9.402026-06-16
3 month+12.5%USD 9.682026-04-17
Year to date+4.81%USD 10.392025-12-31
1 year+70.69%USD 6.382025-07-16
3 year+6.87%USD 10.192023-07-17
5 year-41.45%USD 18.602021-07-16
Since inception-27.4%USD 15.002015-09-16

Kura Oncology Financials at a Glance

Market Cap

$966.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$71.64M

Net Income (TTM)

-$294.57M

EPS (TTM)

-$3.35

P/E Ratio

-3.25

Dividend

$0.00

Beta (Volatility)

1.09 (Average)

Price

$10.89

Volume

814,951

Open

$10.62

Previous Close

$10.86

Daily Range

$10.50 - $10.99

52-Week Range

$5.45 - $12.49

Estimated Earnings Date

Aug 6, 2026

KURA News

Foolcom-Featured.png

Kura (KURA) Revenue Drops 61%

Motley Fool Markets TeamAug 7, 2025
retiree

2 Incredible Growth Stocks to Buy Hand Over Fist

George Budwell, PhDMay 8, 2024
worried-businessman-working-in-office-with-his-coworker-and-having-problems

Why Kura Oncology Stock Is Sliding Today

Cory RenauerNov 24, 2021
GettyImages-1138937146

Why Kura Oncology Is Skyrocketing Today

Prosper Junior BakinyApr 28, 2020
three-distressed-people-getty

3 Beaten-Down Biotech Stocks: Can They Bounce Back?

Cory RenauerOct 25, 2018
Doctor Patient Report

Here's Why Kura Oncology Fell Today

Brian Orelli, PhDOct 22, 2018

KURA: Motley Fool Moneyball Superscore

71

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Kura Oncology

Kura Oncology makes medicines that target specific types of cancer. These drugs help patients whose tumors have certain genetic changes. The company aims to provide more effective treatments for blood and solid tumors.

The Cancer Treatment Pipeline

  • KOMZIFTI (ziftomenib): A daily oral pill approved to treat adults with a specific form of leukemia; it is the first medicine in its class to reach the market.
  • Darlifarnib: An experimental drug currently being tested for kidney and lung cancers; it works by blocking enzymes that help cancer cells grow.
  • Tipifarnib: A first-generation treatment being studied in combination with other drugs for head and neck cancer.

Strategic Alliances and Milestones

  • Entered a major licensing agreement with Kyowa Kirin in November 2024 to co-develop and sell ziftomenib globally.
  • Received FDA approval for its first commercial product, KOMZIFTI, in November 2025 for patients with specific blood cancer mutations.
  • Partnered with Mirati (a BMS company) in October 2023 to evaluate drug combinations in patients with solid tumors.
  • Worked with Novartis to study how its lead drug candidates perform when used alongside existing targeted therapies.

What Makes Kura Stand Out?

Kura uses precision medicine to match specific treatments to patients based on their unique genetic profiles. This approach identifies individuals most likely to benefit from therapy, potentially reducing the time and cost of drug development.

The Numbers Behind the Science

  • Revenue was $17.3 million in Q4 2025, down 67.8% from the previous year.
  • Net income was -$81 million in Q4 2025, as losses deepened 321.5% compared to 2024.
  • Operating cash flow reached $117.3 million in Q4 2025, down 56.4% year-over-year.
  • Market capitalization rose to $914.8 million in Q4 2025, up 20.5% from the prior year.

Bottom Line

Kura Oncology has moved from a research firm to a commercial-stage company with its first approved drug. Its strategy relies on large-scale partnerships and genetic targeting to expand its reach in the oncology market.

AI Generated • May 3, 2026

Industry

Biotechnology

Sector

Health Care

Employees

260

CEO

Troy E. Wilson, PhD

Website

www.kuraoncology.com

Headquarters

San Diego, CA 92121, US

KURA Financials

Key Financial Metrics (TTM)

Gross Margin

94.66%

Operating Margin

-443.54%

Net Income Margin

-411.19%

Return on Equity

-141.95%

Return on Capital

-156.03%

Return on Assets

-45.14%

Earnings Yield

-30.77%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$966.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

88.77M

Volume

814.95K

Avg. Volume

1.79M

Financials (TTM)

Gross Profit

$67.81M

Operating Income

-$317.75M

EBITDA

-$292.27M

Operating Cash Flow

-$77.99M

Capital Expenditure

-$6.47M

Free Cash Flow

-$84.46M

Cash & ST Invst.

$580.82M

Total Debt

$24.27M

Kura Oncology Performance Analysis

Kura Oncology annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 53,883,000N/A
20252025-12-31USD 67,482,00025.2%
Kura Oncology sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-308.4%
Q32025-09-3035.7%
Q42025-12-31-16.5%
Q12026-03-315.4%
Kura Oncology annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.033.1%
20232023-12-31USD -2.082.8%
20242024-12-31USD -2.02-3.1%
20252025-12-31USD -3.1857.4%
Kura Oncology sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-13.6%
Q32025-09-30-13.3%
Q42025-12-31-8.2%
Q12026-03-319.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$18.27M

+29.5%

Gross Profit

$17.65M

+25.1%

Gross Margin

96.62%

N/A

Market Cap

$966.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.72M

N/A

Employees

260

N/A

Net Income

-$73.33M

-27.7%

EBITDA

-$72.63M

-26.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$580.82M

-11.8%

Total Debt

$24.27M

+25.4%

Accounts Receivable

$13.65M

-72.0%

Inventory

$843.00K

N/A

Long Term Debt

$22.99M

+48.1%

Short Term Debt

$1.28M

-66.5%

Return on Assets

-45.14%

N/A

Return on Invested Capital

-57.66%

N/A

Free Cash Flow

-$85.98M

-19.1%

Operating Cash Flow

-$85.85M

-19.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
REPLReplimune Group, Inc.
$10.23+7.46%
EYPTEyePoint Pharmaceuticals, Inc.
$13.30+1.99%
SVRASavara Inc.
$5.52+0.00%
PRMEPrime Medicine, Inc.
$3.13-2.80%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.53-0.02%
AALAmerican Airlines Group
$14.98-0.04%
NOKNokia
$10.12-0.03%
PATHUiPath
$12.15+0.01%

Questions About KURA

What is the current price of Kura Oncology?

Kura Oncology is trading at $10.86 per share.

What is the 52-week range for Kura Oncology?

Over the past 52 weeks, Kura Oncology has traded between $5.45 and $12.49.

How much debt does Kura Oncology have?

As of the most recent reporting period, Kura Oncology reported total debt of $24.27M.

How much cash does Kura Oncology have on hand?

Kura Oncology reported $39.08M in cash and cash equivalents in its most recent financial results.

What is Kura Oncology’s dividend yield?

Kura Oncology does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services